{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:47:53Z","timestamp":1782190073291,"version":"3.54.5"},"reference-count":42,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Lenvatinib is a multi-targeted tyrosine kinase inhibitor that inhibits tumor angiogenesis, but hypertension is the most common adverse reaction. Telmisartan is an angiotensin receptor blocker used to treat hypertension. In this study, a simple ultra-performance liquid chromatography-tandem mass spectrometry method was developed for the simultaneous determination of lenvatinib and telmisartan, and it was applied to the pharmacokinetic drug interaction study. Plasma samples were treated with acetonitrile to precipitate protein. Water (containing 5 mM of ammonium acetate and 0.1% formic acid) and acetonitrile (0.1% formic acid) were used as the mobile phases to separate the analytes with gradient elution using a column XSelect HSS T3 (2.1 mm \u00d7 100 mm, 2.5 \u03bcm). Multiple reaction monitoring in the positive ion mode was used for quantification. The method was validated and the precision, accuracy, matrix effect, recovery, and stability of this method were reasonable. The determination of analytes was not interfered with by other substances in the blank plasma, and the calibration curves of lenvatinib and telmisartan were linear within the range of 0.2\u20131000 ng\/mL and 0.1\u2013500 ng\/mL, respectively. The results indicate that lenvatinib decreased the systemic exposure of telmisartan. Potential drug interactions were observed between lenvatinib and telmisartan.<\/jats:p>","DOI":"10.3390\/molecules27041291","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T22:44:47Z","timestamp":1644965087000},"page":"1291","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Simple UPLC\/MS-MS Method for Simultaneous Determination of Lenvatinib and Telmisartan in Rat Plasma, and Its Application to Pharmacokinetic Drug-Drug Interaction Study"],"prefix":"10.3390","volume":"27","author":[{"given":"Yanjun","family":"Cui","sequence":"first","affiliation":[{"name":"National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei Province General Center, Shijiazhuang 050051, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7651-6543","authenticated-orcid":false,"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei Province General Center, Shijiazhuang 050051, China"},{"name":"Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050051, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[{"name":"National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei Province General Center, Shijiazhuang 050051, China"},{"name":"Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050051, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liju","family":"Fan","sequence":"additional","affiliation":[{"name":"National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei Province General Center, Shijiazhuang 050051, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueru","family":"He","sequence":"additional","affiliation":[{"name":"National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei Province General Center, Shijiazhuang 050051, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Fu","sequence":"additional","affiliation":[{"name":"National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei Province General Center, Shijiazhuang 050051, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5349-4970","authenticated-orcid":false,"given":"Zhanjun","family":"Dong","sequence":"additional","affiliation":[{"name":"National Clinical Drug Monitoring Center, Department of Pharmacy, Hebei Province General Center, Shijiazhuang 050051, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijbiomac.2020.12.009","article-title":"Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer","volume":"168","author":"Zhao","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Pottier, C., Fresnais, M., Gilon, M., J\u00e9rusalem, G., Longuesp\u00e9e, R., and Sounni, N.E. (2020). Tyrosine kinase inhibitors in cancer: Breakthrough and challenges of targeted therapy. Cancers, 12.","DOI":"10.3390\/cancers12030731"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cld.2020.07.012","article-title":"Tyrosine kinase inhibitors and hepatocellular carcinoma","volume":"24","author":"Reig","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-018-0708-8","article-title":"Tyrosine kinase Inhibitor-Induced hypertension","volume":"20","author":"Agarwal","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaccao.2019.08.012","article-title":"Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor","volume":"1","author":"Waliany","year":"2019","journal-title":"JACC Cardio Oncol."},{"key":"ref_7","first-page":"2365","article-title":"Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)","volume":"124","author":"Wirth","year":"2018","journal-title":"Cancer-Am. Cancer Soc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfaa174","article-title":"Tyrosine kinase inhibitor-induced hypertension\u2014marker of anti-tumour treatment efficacy or cardiovascular risk factor?","volume":"14","author":"Ptinopoulou","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jaccao.2019.07.002","article-title":"Renin-Angiotensin-Aldosterone system modulates blood pressure response during vascular endothelial growth factor receptor inhibition","volume":"1","author":"Bottinor","year":"2019","journal-title":"JACC Cardio Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"188391","DOI":"10.1016\/j.bbcan.2020.188391","article-title":"Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy","volume":"1874","author":"Zhao","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1158\/1078-0432.CCR-15-0923","article-title":"Lenvatinib in advanced, radioactive iodine-refractory, differentiated thyroid carcinoma","volume":"21","author":"Yeung","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ckj\/sfaa137","article-title":"Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib","volume":"14","author":"Saito","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-021-00817-2","article-title":"Cardiovascular toxicities of antiangiogenic tyrosine kinase inhibitors: A retrospective, pharmacovigilance study","volume":"16","author":"Goldman","year":"2021","journal-title":"Target. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/pr.112.007278","article-title":"A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists","volume":"65","author":"Michel","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2165\/11206710-000000000-00000","article-title":"Telmisartan: A review of its use in cardiovascular disease prevention","volume":"71","author":"Frampton","year":"2012","journal-title":"Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1517\/14656566.2011.632367","article-title":"Telmisartan: Just an antihypertensive agent? A literature review","volume":"12","author":"Destro","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1124\/dmd.106.012351","article-title":"Rapid identification of p-glycoprotein substrates and inhibitors","volume":"34","author":"Chang","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1517\/17425255.2010.494597","article-title":"Telmisartan: A review of its pharmacodynamic and pharmacokinetic properties","volume":"6","author":"Deppe","year":"2010","journal-title":"Expert Opin. Drug Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00228-020-02879-z","article-title":"Influences of ABC transporter and CYP3A4\/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects","volume":"76","author":"Li","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1038\/s41598-019-41820-y","article-title":"Influence of CYP3A4\/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer","volume":"9","author":"Ozeki","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bcp.12907","article-title":"Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer","volume":"81","author":"Gupta","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/jps.24306","article-title":"Drug\u2013drug interactions related to altered absorption and plasma protein binding: Theoretical and regulatory considerations, and an industry perspective","volume":"104","author":"Hochman","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchromb.2012.01.004","article-title":"Development and validation of LC\u2013MS\/MS assays for the quantification of E7080 and metabolites in various human biological matrices","volume":"887\u2013888","author":"Dubbelman","year":"2012","journal-title":"J. Chromatogr. B"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jpba.2015.05.008","article-title":"A validated LC\u2013MS\/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis","volume":"114","author":"Mano","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_29","first-page":"1","article-title":"Validation of a liquid Chromatography-Tandem mass spectrometric assay for quantitative analysis of lenvatinib in human plasma","volume":"2017","author":"Sano","year":"2017","journal-title":"Int. J. Anal. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zanchetta, M., Iacuzzi, V., Posocco, B., Bortolin, G., Poetto, A.S., Orleni, M., Canil, G., Guardascione, M., Foltran, L., and Fanotto, V. (2021). A rapid, simple and sensitive LC-MS\/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0259137"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"114360","DOI":"10.1016\/j.jpba.2021.114360","article-title":"UPLC-MS\/MS method for the determination of Lenvatinib in rat plasma and its application to drug-drug interaction studies","volume":"206","author":"Cui","year":"2021","journal-title":"J. Pharm. Biomed."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jchromb.2005.09.021","article-title":"Determination of telmisartan in human plasma by liquid chromatography\u2013tandem mass spectrometry","volume":"828","author":"Li","year":"2005","journal-title":"J. Chromatogr. B"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jpha.2012.03.008","article-title":"Simultaneous determination of telmisartan and amlodipine in human plasma by LC\u2013MS\/MS and its application in a human pharmacokinetic study","volume":"2","author":"Ravi","year":"2012","journal-title":"J. Pharm. Anal."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jpba.2008.08.021","article-title":"Liquid chromatographic\u2013tandem mass spectrometric method for the simultaneous quantitation of telmisartan and hydrochlorothiazide in human plasma","volume":"48","author":"Yan","year":"2008","journal-title":"J. Pharm. Biomed."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jpha.2017.05.004","article-title":"Development and validation of a high throughput LC\u2013MS\/MS method for simultaneous quantitation of pioglitazone and telmisartan in rat plasma and its application to a pharmacokinetic study","volume":"7","author":"Sengupta","year":"2017","journal-title":"J. Pharm. Anal."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jpba.2016.09.006","article-title":"Simultaneous determination of telmisartan and pitavastatin in rat plasma by UPLC\u2013MS\/MS: Application to pharmacokinetic interaction study","volume":"131","author":"Chen","year":"2016","journal-title":"J. Pharm. Biomed."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S1470-2045(20)30069-3","article-title":"Clinical implications of food-drug interactions with small-molecule kinase inhibitors","volume":"21","author":"Veerman","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"105773","DOI":"10.1016\/j.ejps.2021.105773","article-title":"Improved in vitro and in vivo properties of telmisartan in the co-amorphous system with hydrochlorothiazide: A potential drug-drug interaction mechanism prediction","volume":"161","author":"Shi","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_39","first-page":"659","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Nihal","year":"2007","journal-title":"FASEB J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s12272-012-1017-7","article-title":"Pharmacokinetic interactions of clopidogrel with quercetin, telmisartan, and cyclosporine a in rats and dogs","volume":"35","author":"Lee","year":"2012","journal-title":"Arch. Pharm. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00228-016-2130-1","article-title":"Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin","volume":"72","author":"Hu","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_42","first-page":"308","article-title":"Study on the Pharmacokinetics interaction of telmisartan and rosiglitazone in rat","volume":"26","author":"Wu","year":"2006","journal-title":"Chin. J Pharm Anal."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/4\/1291\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:19:44Z","timestamp":1760134784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/4\/1291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["molecules27041291"],"URL":"https:\/\/doi.org\/10.3390\/molecules27041291","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]}}}